Molecular Partners AG Sponsored ADR (MOLN)
(Real Time Quote from BATS)
$6.14 USD
+0.10 (1.58%)
Updated Aug 12, 2024 03:14 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Molecular Partners AG Sponsored ADR (MOLN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$8.37 | $15.00 | $4.10 | 38.58% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Molecular Partners AG Sponsored ADR comes to $8.37. The forecasts range from a low of $4.10 to a high of $15.00. The average price target represents an increase of 38.58% from the last closing price of $6.04.
Analyst Price Targets (3 )
Broker Rating
Molecular Partners AG Sponsored ADR currently has an average brokerage recommendation (ABR) of 2.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 2.33 a month ago based on three recommendations.
Of the three recommendations deriving the current ABR, one is Strong Buy, representing 33.33% of all recommendations. A month ago, Strong Buy represented 33.33%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/MOLN.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.33 | 2.33 | 2.33 | 2.33 | 2.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/1/2024 | Cowen & Co. | Michael Nedelcovych | Strong Buy | Strong Buy |
5/16/2024 | SVB Securities | Daina M Graybosch | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.33 |
ABR (Last week) | 2.33 |
# of Recs in ABR | 3 |
Average Target Price | $8.37 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 75 of 253 |
Current Quarter EPS Est: | NA |